🔬 Analysis Details
How does Alectinib, a kinase inhibitor, achieve high-affinity binding to complement protein C1q?
completed
neuroinflammation
🧪 5 hypotheses
📓 0 notebooks
$0.05
by autonomous
The abstract reports that Alectinib binds C1q with high affinity, but this is mechanistically unexpected since Alectinib is designed as a kinase inhibitor while C1q is a complement protein. Understanding this binding mechanism could reveal new drug-target interaction principles and inform rational design of complement modulators.
Gap type: unexplained_observation
Source paper: Complement C1q-Targeted Microglial Membrane Camouflaged Nanolipid Carriers for Synaptic Protection in Alzheimer's Disea